[A clinico-experimental study of the tocolytic properties of salbupart in treating threatened abortion].
Clinical and experimental studies have revealed that salbupart, a beta-mimetic agent, administered in a dose of 0.14 mg/kg (the maximal therapeutic dose) markedly inhibited the spontaneous and oxytocin-induced uterine contractility, caused no embryotoxic or teratogenic effects, and did not influence fetal growth and development. The efficacy of salbupart tocolytic therapy was estimated as 75%. Blood plasma cAMP levels normalized in the pregnant women over the course of therapy. Clinical and experimental results recommend salbupart for pregnancy protecting therapy in cases with threatened spontaneous abortions.
Murashko
L E
LE
Sheveleva
G A
GA
Strel'chenko
N V
NV
Filimonov
V G
VG
Sidel'nikova
V M
VM
D000033:Abortion, Threatened / Q000188:drug therapy* / Q000503:physiopathology; D000420:Albuterol / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D051381:Rats; D015149:Tocolytic Agents / Q000627:therapeutic use* / Q000633:toxicity; D014590:Uterine Contraction / Q000187:drug effects
D015149:Tocolytic Agents; D005280:Fenoterol; D000420:Albuterol
Kliniko-éksperimental'noe izuchenie tokoliticheskikh svoĭstv sal'buparta pri lechenii ugrozhaiushchikh prezhdevremennykh rodov.